Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Johnson and Johnson
McKinsey
Medtronic

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for ASP1517

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug ASP1517: Patents, clinical trial progress, indications

ASP1517 is an investigational drug.

There have been 24 clinical trials for ASP1517. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Inc, and Astellas Pharma Europe B.V.

There are twenty-eight US patents protecting this investigational drug and one hundred and ninety international patents.

Recent Clinical Trials for ASP1517
TitleSponsorPhase
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation iFibroGenPhase 1
A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation iAstellas Pharma Global Development, Inc.Phase 1
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion BurdenAstraZenecaPhase 3

See all ASP1517 clinical trials

Clinical Trial Summary for ASP1517

Top disease conditions for ASP1517
Top clinical trial sponsors for ASP1517

See all ASP1517 clinical trials

US Patents for ASP1517

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP1517   Start Trial Nitrogen-containing heteroaryl compounds and methods of use thereof FibroGen, Inc. (San Francisco, CA)   Start Trial
ASP1517   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
ASP1517   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Express Scripts
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.